Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,707 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,707 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Enrollment posture brief
Registry condition prostate-cancer
OPEN 275 | RECR 37% | LATE 75 | EARLY 344 | RANK #4 | SPON 53
Volume-matched condition peers
Nearest open-share peer: Chronic Disease (37% recruiting · 49 trials)
Prostate Cancer lists 275 open slots (37% of 749 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 7 of 15
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Alliance for Clinical Trials in Oncology
NCT00430183
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT03574571
Improving Care After Inherited Cancer Testing
Vanderbilt-Ingram Cancer Center
NCT04763915
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Candel Therapeutics
NCT01436968
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT04644068
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
University of Alabama at Birmingham
NCT04000880
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
NCT03348670
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Pfizer
NCT04821622
Prostate Imaging Using MRI +/- Contrast Enhancement
University College, London
NCT04571840
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
Boston Scientific Corporation
NCT04905069
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
Myriad Genetic Laboratories
NCT04404894
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus
NCT03860272
Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Massachusetts General Hospital
NCT01617161
Surveillance or Focal Therapy
Kaiser Permanente
NCT07207902
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
Francis Medical
NCT05683691
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Eli Lilly and Company
NCT03706365
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Pfizer
NCT04557449
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
Dana-Farber Cancer Institute
NCT03141671
Leveraging EA8191 to Assess AI-Augmented EHR Abstraction
University of Pennsylvania
NCT06561230
Brachytherapy for Prostatic Carcinoma Patients
M.D. Anderson Cancer Center
NCT00525720
Marker Driven Selection of Patients for Prostate Biopsy and Management
University of Miami
NCT04240327
3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer
University of Cincinnati
NCT01653093
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Lantheus Medical Imaging
NCT06074510
Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome
City of Hope Medical Center
NCT01441687
Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies
National Cancer Institute (NCI)
NCT04541030
Validation Study on the Impact of Decipher® Testing - VANDAAM Study
H. Lee Moffitt Cancer Center and Research Institute
NCT02723734
Characterization of Prostate Cancer With 3T MR
Beth Israel Deaconess Medical Center
NCT00831142
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
NCT04025372
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older
Memorial Sloan Kettering Cancer Center
NCT00579072
SpaceIT Hydrogel System for Perirectal Spacing
Boston Scientific Corporation
NCT06451614
Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II)
University of California, San Francisco
NCT03999151
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
Profound Medical
NCT05027477
A Study of Cognitive Health in Survivors of Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT05540782
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Abramson Cancer Center at Penn Medicine
NCT05096338
Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
Medical College of Wisconsin
NCT03971591
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
RTOG Foundation
NCT03809000
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Candel Therapeutics
NCT02768363
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
National Cancer Institute (NCI)
NCT03976843
Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy
M.D. Anderson Cancer Center
NCT01410942
Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics
NCT05546268
Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy
University of Miami
NCT02307058
Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer
University of Miami
NCT01794403
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
University of California, San Francisco
NCT02735252
Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer
Proton Collaborative Group
NCT01230866
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer
Profound Medical
NCT02766543
Rectal Spacers in Prostate Cancer Patients Undergoing Radiation Therapy
Advanced Radiation Centers of New York
NCT06599476
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03471650
A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life
Complement Theory
NCT06397651
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Medtronic - MITG
NCT05696444
The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT03808077
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer page
749 registered trials, 275 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 275 Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer condition card totals 749 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.